Federal And State Policy
Our team monitors qualitative and quantitative trends and policy and legislation in real time. We create customized models to inform successful strategies and tactics so you can act decisively.
Find Out MoreSound Strategic Advice.
Deep Experience.
A 360º Perspective.
ADVI Health is the strategic consulting partner to the healthcare and life sciences ecosystem.
We solve complicated problems in healthcare with data-informed commercialization, market access, and policy expertise. Through our deep expertise, global reach, and end-to-end solutions and tools, we help our clients create value, accelerate growth, and provide answers to their most important big questions and decisions.
Our sagacity. Your success.
Market Access and Pricing Strategy
We help your best ideas become market leaders. Regardless of where you are in the product life cycle, we can take it to the next level. We create and communicate value, accelerate growth, optimize access, and confidently navigate the shifting market landscape.
Find Out More
Strategic Analytics. Value and Economics
Your product must pass muster with payers. We help you define, measure, and report value across settings of care, prospective payment systems, and insurance benefit structures.
Find Out More
Coding and Reimbursement
Understanding Medicare, Medicaid, VA-DOD, and private payers is vital. There is no easy button. We help you stay ahead of changing regulations and ensure you are prepared for what’s next.
Find Out More
Financial Services Due Diligence
Thinking like investors, we deliver customized, deep, data-driven analysis to quantify relevant risks, opportunities, and trends to inform financial models and recommend how to achieve goals.
Find Out More
ADVI is our go-to partner for market access and reimbursement advice. They have a breadth and depth of experience through their partners and advisors. They’ve provided sound guidance around strategy, evidence development, and coding for molecular diagnostics. We can confidently attest that ADVI has had a hand in helping with our most significant wins.Senior Vice President, Payer Strategy and Revenue Cycle Management
Work That We’re Proud Of
Prostate Cancer Prognostic Assay
ADVI created a comprehensive payer launch engagement strategy for a prostate cancer prognostic assay, including timelines for engagement, strategic communication approaches, and a targeted group of payers known to be early adopters.
Physician-Administered Drugs
ADVI provided expert-informed insights and predictions related to recent commercial market developments and trends that threaten the buy-and-bill structure for physician-administered drugs.
Diabetic Devices and Supplies
ADVI tracked historical CMS reimbursement changes for diabetic devices and supplies and evaluated the impact Medicare payment rates had on commercial pricing, so the client was able to better understand and prepare internal forecasting for how newly-proposed regulations may affect commercial plan rates in the future.
Biopharmaceutical Policy Analysis and Advocacy Strategy
ADVI worked with a premier industry trade association on legislative, regulatory and market access issues across government payers and commercial markets. Advised advocacy strategy with policy reform recommendations, informed by analysis of implications across industry, patients, providers and payers.
Seize The Opportunity
Leverage our Expertise
Schedule a consultation on your current challenge.
Submit an RFP
Submit an RFP and let’s determine how our team of experts can support your business.
Keep Me Informed
Get our incisive analysis delivered straight to your inbox.Submit an RFP
Submit an RFP and let’s determine how our team of experts can support your business.Interested in hearing more from us ?
;
In a new episode of OBR Oncology's Leading Thoughts on the Business and Policy of #oncology podcast, #ADVIExpert Michael Kolodziej, MD, is joined by industry experts to discuss the #IRA's downstream effects on oncology practice. Tune in to the episode: https://www.obroncology.com/leading-thoughts/this-is-a-big-deal-the-ira-will-change-practice